Krystal Biotech Inc (KRYS)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	89,159	52,372	105,939	57,161	10,932	-29,812	-140,409	-135,307	-139,975	-129,729	-115,468	-103,723	-69,570	-58,147	-52,168	-42,638	-32,167	-27,141	-21,803	-20,318
Revenue (ttm)	US$ in thousands	293,354	247,796	172,511	103,808	58,154	10,946	2,390	809	0	0	0	0	0	0	0	0	0	0	0	542
Net profit margin		30.39%	21.14%	61.41%	55.06%	18.80%	-272.36%	-5,874.85%	-16,725.22%	—	—	—	—	—	—	—	—	—	—	—	-3,748.71%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $89,159K ÷ $293,354K
= 30.39%

Krystal Biotech Inc's net profit margin has shown significant fluctuations over the reported periods. The net profit margin as a percentage of revenue provides insight into the company's profitability.

As of March 31, 2020, the net profit margin was -3,748.71%, indicating that the company incurred substantial losses relative to its revenue during that period. The negative percentage suggests that the company's expenses exceeded its revenue.

For the subsequent quarters up to December 31, 2021, the net profit margin data is unavailable (indicated by "—"), making it challenging to assess the company's profitability during those periods.

Starting from March 31, 2023, the net profit margin continued to fluctuate. It turned significantly negative at -16,725.22% before dropping to -5,874.85% in June 30, 2023, suggesting continued losses relative to revenue.

However, the trend changed in the later periods, with the net profit margin improving to -272.36% in September 30, 2023, and finally turning positive at 18.80% by December 31, 2023. This positive margin indicates that the company generated profit after covering its expenses.

The positive trend continued into the subsequent quarters with further improvement in profitability. By December 31, 2024, Krystal Biotech Inc achieved a net profit margin of 30.39%, indicating a strong profitability position as the company kept a higher proportion of revenue as profit.

Overall, the net profit margin trend suggests that Krystal Biotech Inc experienced challenges with profitability initially but later made significant improvements, ultimately achieving a healthy net profit margin by December 31, 2024. It is essential for stakeholders to monitor this metric to assess the company's financial health and operational efficiency.